hydroxychloroquine has been researched along with Stroke in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 8.31 | Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( Avina-Zubieta, JA; Choi, H; Esdaile, JM; Jorge, A; Lacaille, D; Lu, N, 2023) |
| "Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE." | 8.02 | Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. ( Goldman, DW; Konig, MF; Li, J; Petri, M, 2021) |
| "To investigate the effects of hydroxychloroquine, sulfasalazine and methotrexate on ischemic stroke in patients with rheumatoid arthritis (RA)." | 7.88 | Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study. ( Chen, CH; Chen, CM; Chiou, JY; Leong, PY; Li, YC; Lin, LC; Tam, HW; Wang, YH; Wei, JC, 2018) |
| "We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 4.31 | Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( Avina-Zubieta, JA; Choi, H; Esdaile, JM; Jorge, A; Lacaille, D; Lu, N, 2023) |
| "Hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE." | 4.02 | Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. ( Goldman, DW; Konig, MF; Li, J; Petri, M, 2021) |
| " We illustrate our approach in the context of an RCT of hydroxychloroquine on pneumonia in COVID-19 patients and a cumulative meta-analysis of the effect of antihypertensive treatments on stroke." | 4.02 | Hypothetical case replacement can be used to quantify the robustness of trial results. ( Dietz, T; Frank, KA; Hayter, CS; Kolak, M; Lin, Q; Mahmoud, RA; Maroulis, S; Mueller, AS; Rosenberg, JM; Xu, R; Zhang, L, 2021) |
| "To investigate the effects of hydroxychloroquine, sulfasalazine and methotrexate on ischemic stroke in patients with rheumatoid arthritis (RA)." | 3.88 | Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study. ( Chen, CH; Chen, CM; Chiou, JY; Leong, PY; Li, YC; Lin, LC; Tam, HW; Wang, YH; Wei, JC, 2018) |
| "Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease." | 1.51 | Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. ( Bijl, M; Bultink, IEM; de Leeuw, K; Dolhain, RJEM; Fritsch-Stork, R; Groot, N; Kamphuis, S; Shaikhani, D; Teng, YKO; Zirkzee, E, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Jorge, A | 1 |
| Lu, N | 1 |
| Choi, H | 1 |
| Esdaile, JM | 1 |
| Lacaille, D | 1 |
| Avina-Zubieta, JA | 1 |
| Petri, M | 1 |
| Konig, MF | 1 |
| Li, J | 1 |
| Goldman, DW | 1 |
| Frank, KA | 1 |
| Lin, Q | 1 |
| Maroulis, S | 1 |
| Mueller, AS | 1 |
| Xu, R | 1 |
| Rosenberg, JM | 1 |
| Hayter, CS | 1 |
| Mahmoud, RA | 1 |
| Kolak, M | 1 |
| Dietz, T | 1 |
| Zhang, L | 1 |
| Tam, HW | 1 |
| Chen, CM | 1 |
| Leong, PY | 1 |
| Chen, CH | 1 |
| Li, YC | 1 |
| Wang, YH | 1 |
| Lin, LC | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Groot, N | 1 |
| Shaikhani, D | 1 |
| Teng, YKO | 1 |
| de Leeuw, K | 1 |
| Bijl, M | 1 |
| Dolhain, RJEM | 1 |
| Zirkzee, E | 1 |
| Fritsch-Stork, R | 1 |
| Bultink, IEM | 1 |
| Kamphuis, S | 1 |
| Montejo, M | 1 |
| Goikoetxea, J | 1 |
| Mularoni, A | 1 |
| Blanco, MJ | 1 |
| Gaafar, A | 1 |
| Boado, MV | 1 |
| Marín, M | 1 |
| Aramendi, JI | 1 |
| Kurtzman, DJ | 1 |
| Ho, A | 1 |
| Wright, NA | 1 |
| Rubenstein, MH | 1 |
| Vleugels, RA | 1 |
7 other studies available for hydroxychloroquine and Stroke
| Article | Year |
|---|---|
Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; British Columbia; Case-Control Studies; Humans; Hydroxy | 2023 |
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Chromatography, Liquid; Female; Fingers; Gangrene; Humans; Hydroxychlor | 2021 |
Hypothetical case replacement can be used to quantify the robustness of trial results.
Topics: Antihypertensive Agents; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Meta-Analysis as Topic | 2021 |
Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Humans; Hydroxychloroquine; | 2018 |
Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antiphospholipid; Antirheumatic Agents; Child; Ch | 2019 |
[Tropheryma wipplei endocarditis: a report of 3 cases].
Topics: Actinomycetales Infections; Anti-Bacterial Agents; Anticoagulants; Doxycycline; Drug Therapy, Combin | 2013 |
Unilateral Gottron Papules in a Patient Following a Stroke: Clinical Insights Into the Disease Mechanisms and Pathophysiology of Cutaneous Dermatomyositis.
Topics: Biopsy, Needle; Dermatomyositis; Drug Therapy, Combination; Female; Hand Dermatoses; Humans; Hydroxy | 2016 |